Oral toxicity produced by chemotherapy: A systematic review

Begonya Chaveli-López

Valencia University Medical and Dental School, Valencia, Spain

Abstract

Introduction: Antineoplastic chemotherapy remains one of the most widely used management strategies in cancer, either alone or in combination with other types of treatment. The main inconvenience of chemotherapy is its lack of selectivity, since it acts upon both tumor cells and rapidly multiplying normal cells such as bone marrow cells, hair follicle cells and oral and gastrointestinal mucosal cells.

Material and method: An exhaustive search was made of the main oral toxic effects of chemotherapy in the PubMed-Medline, Cochrane Library and Scopus databases. A total of 1293 articles were identified, of which 333 met the study inclusion criteria.

Results: The toxic effects of chemotherapy at oral mucosal level comprise mucositis, osteonecrosis of the jaws secondary to bisphosphonate use, susceptibility to infections, dental alterations, salivary and neurological disorders, dysgeusia and bleeding tendency. These complications have a negative impact upon patient quality of life, and in some cases can prove life-threatening.

Conclusions: Evaluation of patient oral and dental health is essential before administering chemotherapy, in order to minimize the risk of oral and systemic complications of such treatment.

Key words: Chemotherapy, oral complications, dental, saliva and osteonecrosis jaw.

Introduction

In global terms, cancer is characterized by increased cell proliferation and diminished apoptosis (1). The proliferation of atypical cells gives rise to invasive capacity, with the infiltration of body tissues or organs through the bloodstream or lymphatic system – this process being known as metastasis. The existing cancer treatments comprise surgery and radiotherapy, chemotherapy, biological or immune therapy, hormonal therapy and gene therapy (a form of treatment that is still in the investigational stage) (2), which aim to block cell proliferation (1). Despite the advances in cancer management, chemotherapy remains one of the most widely used treatment modalities, either alone or in combination with other types of treatment (3,4). The great inconvenience of chemotherapy is its lack of selectivity, since it acts upon both tumor cells and rapidly multiplying normal cells (1,3-5).

The oral cavity is very susceptible to the direct and indirect toxic effects of chemotherapy. This is due to a num-
Oral toxicity due to chemotherapy

Oral toxicity produced by the administration of chemotherapy

The oral complications of chemotherapy are either a result of direct action of the drug upon the oral mucosa (direct stomatological toxicity), or an indirect consequence of chemotherapeutic drug-induced bone marrow suppression or myelosuppression (indirect stomatological toxicity) (3,4).

1. Mucosal toxicity

The cells of the oral cavity have a fast turnover rate, with a cycle of 7-14 days. This explains the special susceptibility of the oral mucosa to the toxic effects of cytostatic drugs (3).

- Terminology

There is some debate regarding the terminology used in reference to the mucosal alterations produced by cancer treatment. Some authors prefer the term “stomatitis”, since the term “mucositis” can refer to any mucosal membrane of the gastrointestinal tract (6). However, there appears to be agreement in the international literature on the use of the term “oral mucositis” or “buccal mucositis”. This term, introduced in the late 1980s, refers to inflammation of the oral mucosa induced by radiotherapy (seen in 80% of all patients), chemotherapy (in approximately 40-50%), or bone marrow transplantation (in over 75% of all patients), and is considered a manifestation of leukopenia (4,6).

- Physiopathology

The pathogenesis of oral mucositis has not been fully clarified. According to the hypothesis of Sonis et al., mucositis comprises four phases. The first phase (inflammation of factors, including the high cellular turnover rate of the oral mucosa, the complex and diverse microflora of the oral cavity, and oral tissue trauma occurring during normal oral function (3,4). It is therefore essential to evaluate the oral condition of the patient and to stabilize any oral disease conditions before cancer treatment is provided (5). Oncological patient care must be viewed from both the preventive and therapeutic perspectives, in order to minimize the risk of oral complications and other related systemic complications (4).

The present systematic review offers an update on the main oral toxic effects of chemotherapy, based on the data found in the scientific literature.

Material and Methods

An exhaustive search was made of the PubMed-Medline, Cochrane Library and Scopus databases, using the following keywords: “oral complications”, “oral mucositis”, “oral candidiasis”, “periodontal disease”, “gingivitis”, “caries”, “oral infection”, “dental development”, “dysgeusia”, “taste disturbances”, “saliva” and “osteonecrosis jaw”, related by means of the boolean operators “AND” and “NOT” to the terms “chemotherapy” and “radiotherapy”, respectively. We included human studies as well as reviews published in English or Spanish during the last 10 years (from January 2002 to December 2012). Opinion articles, series with fewer than 5 cases, and studies involving radiotherapy and/or the bone marrow transplantation as sole or concomitant treatments were excluded. A total of 1293 articles were identified, of which 333 met the study inclusion criteria (Table 1).

| DISORDER                                        | PUBMED | COCHRANE | SCOPUS | TOTAL | TYPE OF STUDY |
|------------------------------------------------|--------|----------|--------|-------|---------------|
| ORAL COMPLICATIONS                              | N      | n        | N      | n     | n* Tri-         |
|                                               |         |          |        |       | al Cohort Case- | control Cross- |
|                                               |         |          |        |       | sectional Case | series Revi-  |
| ORAL MUCOSITIS                                 | 23     | 12       | 4      | 1     | 89 28 116 47 15 |
|                                               |         |          |        |       | 6 4 5 4 13     |
| DENTAL DEVELOPMENT                             | 202    | 127      | 36     | 25    | 93 25 331 116 51 |
|                                               |         |          |        |       | 12 4 7 2 40    |
| DYSGEUSIA                                      | 15     | 5        | 0      | 0     | 48 6 63 6 0 0 5 1 0 0 |
| TASTE ALTERATIONS                              | 19     | 6        | 3      | 3     | 22 8 44 12 3 4 0 0 4 |
| SALIV                                        | 49     | 9        | 8      | 1     | 26 4 74 13 1 2 4 1 0 1 1 4 |
| CANDIDIASIS                                    | 26     | 12       | 35     | 4     | 18 8 79 28 7 4 1 2 2 1 13 |
| PERIODONTAL DISEASE, GINGIVITIS, CARRIES, VIRAL INFECTIONS | 162     | 30       | 22     | 0     | 30 4 214 27 1 11 2 5 4 4 |
| BRONJ                                          | 72     | 33       | 18     | 2     | 275 60 365 79 9 7 3 2 14 44 |
| TOTAL                                          | 562    | 257      | 129    | 39    | 602 143 1293 333 88 |
|                                               |         |          |        |       | 47 23 24 27 124 |
Oral toxicity due to chemotherapy

Antitumor antibiotics
- Anthracyclines
- Antimetabolites
- Others
- Taxanes
- Vinca alkaloids

Table 2. Principal chemotherapeutic drugs capable of causing oral mucosal lesions. *Cytostatic drugs that most often produce mucositis.

| Alkylating agents | Antimunocytar antibiotics | Antimetabolites |
|-------------------|---------------------------|-----------------|
| Busulfan          | Actinomycin D             | Cytosine arabinoside |
| Cyclophosphamide  | Amsacrine                 | 5-fluorouracil*   |
| Mechlorethamine   | Bleomycin                 | Hydroxyurea      |
| Procarbazine      | Mitomycin C               | Methotrexate*    |
| Thiotepa          | Mitomycin                 | 6-mercaptopurine |
|                   |                           | 6-thioguanine    |

| Vinca alkaloids   | Anthracyclines | Taxanes | Others         |
|-------------------|----------------|---------|----------------|
| Vinblastine*      | Daunorubicin   | Docetaxel| Etoposide*     |
| Vincristine       | Doxorubicin*   | Paclitaxel| Teniposide    |
| Vinorelbine       | Epirubicin     |                      | Nitrogenated mustards |

- Risk factors

A number of risk factors influencing the frequency and severity of mucositis have been described. Some are inherent to the patient, such as the type of tumor (hematological disease)(6,8), age (young patients)(6), oral and dental health (poor oral hygiene before and during chemotherapy)(9), the nutritional condition of the patient, and the maintenance of liver and kidney function. In turn, other risk factors are related to the administered drug, such as the type of cytostatic agent used (Table 2)(10), the frequency of administration (prolonged or repeated low-dose administration), and concomitant treatment in the form of radiotherapy and/or bone marrow transplantation (1).

- Clinical characteristics

Mucositis manifests as reddening (erythema), edema or ulceration that can be accompanied by a mild burning sensation. Extreme presentations in turn are characterized by large and painful ulcers that have a strong impact upon patient quality of life – limiting basic functions such as speech, eating or the swallowing saliva (2-4). These manifestations appear shortly after the start of treatment. In 18-40% of all cases they develop after administration of the first chemotherapy cycle (6). Peak symptoms expression is reached after one week, followed by gradual resolution within 2-3 weeks after the end of chemotherapy, provided there is no bone marrow suppression. Mucositis can often become overinfected, mainly with herpes simplex virus or Candida albicans, particularly in patients with prolonged neutropenia.

- Evaluation

A number of systems have been developed for measurement and quantification of the oral epithelial changes, including general scales, multiple variable scores, and treatment-specific classifications (6). At present, the general scale of the World Health Organization (WHO) is the most widely used system in research, combining the clinical appearance of the mucosa with the capacity of the patient to swallow food (4-6,8). In contrast, in the clinical setting, the most commonly used system is the treatment-specific classification pertaining to the Common Toxicity Criteria for Adverse Events of the United States National Cancer Institute (NCI), which encompasses the patient symptoms, the capacity to swallow food, and the need for treatments (1).

- Diagnosis

The diagnosis of mucositis is established from the clinical characteristics. As complementary tests, studies can be made of lesion samples when overinfection due to Candida, herpes simplex virus or bacteria is suspected. In addition, a blood test can prove useful, since neutropenia, thrombopenia and dehydration are often associated. The differential diagnosis includes viral, bacterial and fungal oropharyngeal infections, and graft-versus-host disease. These are disorders requiring careful consideration, and which require specific and timely management (1).

- Treatment and prevention

Correct oral hygiene and a good gingival condition during chemotherapy are associated to a lesser incidence and severity of mucositis (4,9). Regarding the use of drugs or substances for the prevention and treatment of mucositis, the literature offers contradictory information (1,3,8,9). Good results have been reported with the application of ice before and during chemotherapy (1,4,8), and also with the use of iseganan hydrochloride (11). However, the systematic review published by Worthington et al. (12) found that a number of the treatments used for
the prevention of mucositis (amifostine, benzidine, calcium phosphate, Chinese traditional medicine, etoposide in bolus form, honey, hydrolytic enzymes, pieces of ice, iseganan, oral care and zinc sulfate) offer only limited benefit, and their application moreover depends upon the characteristics of the patient. Other treatment such as palifermin (13), oral glutamine (14), granulocyte colony stimulating factor (G-CSF) and macrophages in rinses, the topical application of polyvinylpyrrolidone (PVP) and hyaluronic acid (15), and low-intensity laser phototherapy, have been related to a decrease in the appearance and severity of mucositis (1). Although no treatment has been shown to successfully eliminate mucositis, management of the pain symptoms with anesthetic solutions and, according to recent studies, with morphine in the form of rinses (1,4,8), can help lessen oral discomfort and improve patient quality of life. The use of artificial saliva or cholinergic agonists, and the intake of abundant liquids for the prevention of hyposalivation, help preserve the integrity of the oral mucosa (8). On the other hand, alcohol and smoking should be avoided. Antifungals in suspension or as pomades, either isolatedly or in combination with chlorhexidine, are used for the prevention and treatment of overinfection with Candida (16).

2. Dental alterations
Chemotherapy can cause a range of aesthetic and functional dental problems, mostly in children treated before 5 years of age. However, prepubertal children are also at risk of suffering such late effects (17).

- Physiopathology
In contrast to radiotherapy, which only affects the cells of the irradiated zone, chemotherapy exerts a systemic effect. Due to the short half-life of cytostatic drugs, the dental defects are generally localized, and are secondary to transient changes in odontoblast function, rather than apoptosis (4,17).

• Crown and root morphology
The shape and size of the crown in the temporal dentition are not affected, since crown morphology is determined before birth. However, in the case of the permanent dentition, we can observe macrodontia with a prevalence of 2-2.5%, due to the action of certain chemotherapeutic drugs such as vinblastine and vincristine upon the mature odontoblasts and ameloblasts (17). Chemotherapy also causes morphological anomalies of the dental roots. In this context, in children under 5 years of age we can observe alterations of the roots of the upper and lower premolars, while older children show alterations of the roots of the upper and lower molars, premolars and canines (17). The action of cytostatic drugs upon the microtubules of the odontoblasts interrupts the formation of collagen fibrils and dentinal matrix secretion, giving rise to thin and sharp-pointed roots.

• Agenesis-hypodontia
Intensive chemotherapy, or chemotherapy involving several treatment cycles in the initial stages of hard tissue formation, can give rise to dental agenesis (17, 18).

• Dental hypoplasia
Hypoplasia is characterized by small grooves, point defects and fissures in the enamel in mild cases, horizontal rows of deep grooves in severe cases, and the absence of dental enamel in extreme cases (17). Vincristine, vinblastine and cyclophosphamide are the drugs most commonly related to the appearance of hypoplasias, discolorations and opacification of the enamel, due to their action upon odontogenesis (18).

• Caries
Some authors have described an increased incidence of caries in children subjected to chemotherapy, though the data are controversial, since caries may result from an increased use of rinses, often with a high sugar content, to treat hyposalivation (17,18). In adults, a number of studies have reported an increase in caries in patients subjected to chemotherapy (3,7).

- Treatment
Although the effects of cancer treatment upon the oral cavity are inevitable, a series of measures should be adopted to ensure that their impact upon patient quality of life is minimized. Children scheduled for chemotherapy should undergo a thorough clinical and radiological evaluation by the dentist (4,17). Periodic checks should be made, every 6 months, with tartrectomy and the application of fluor in the dental office. The recommended tooth brushing frequency varies, though at least two daily brushings are advised, using fluorated toothpaste (17). Chlorhexidine varnish also can be applied twice a day as a preventive measure against caries (10,17).

3. Neurological disorders
- Etiology
Certain types of chemotherapeutic drugs, such as vincristine and vinblastine, can exert direct neurotoxic effects (4).

- Clinical characteristics
Neurotoxicity accounts for 6% of all oral complications, causing discomfort and pain similar to that of pulpitis. The pain sensation is constant and of sudden onset, affecting the region of the lower molars in the absence of dental disease.

- Treatment
An oral and radiological exploration should be made to distinguish the pain from that of pulp origin. The symptoms usually disappear one week after chemotherapy. In some cases dental hypersensitivity can manifest weeks or months later. In these cases topical fluoride or the use of a desensitizing toothpaste may lessen the symptoms (4).

4. Salivary alterations
Saliva plays an important role in the modulation of oral health. In this context, deficits in the amount and quality
of the gland secretions can exert negative effects upon oral mucosal health (17).

- Salivary immunoglobulins

Chemotherapy has been shown to affect a series of salivary components, such as immunoglobulins, peroxidases, amylases and other proteins. Salivary immunoglobulins protect the mucosa against traumas and microbial infections. A decrease in the salivary production of immunoglobulins IgG and IgA could explain some of the oral complications of chemotherapy. In this sense, a decrease in IgA has been associated to the appearance of mucositis in patients receiving chemotherapy (10). Jankovic et al., in a study of the effects of cytostatic drugs such as anthracycline and 5-FU in 40 patients with different metastatic tumors, recorded lower IgA levels and higher IgG concentrations in unstimulated saliva versus the control group, with an IgG/IgA ratio of 1.53 in patients with mucositis, while the healthy subjects presented values of under 1.0 (10).

- Salivary pH and chemotherapy

Some authors have reported a modification in salivary buffer capacity after the administration of chemotherapy (19). However, other investigators such as Avşar et al. (17) or Rojas-Morales et al. (19) have observed no significant variations following the administration of cytostatic agents.

- Xerostomia

Chemotherapy can give rise to a temporary but clinically significant decrease in salivary flow that improves as the bone marrow recovers (4,17). Such a decrease in salivary flow in turn favors the appearance of mucositis (1,6-9). The symptoms of xerostomia or dry mouth include dryness, burning sensation or discomfort (particularly of the tongue), cracked lips, changes in the tongue surface, and problems in wearing removable dentures or drinking liquids. The condition tends to be preceded by a metallic taste sensation that subsequently can lead to dysgeusia and glossodynia secondary to the effects of chemotherapy upon the tongue papillae and demineralization of the nerve fibers (7,10). In treating xerostomia it is advisable to maintain adequate oral hydration by means of the regular intake of water, the use of saliva substitutes or cholinergic agonists such as pilocarpine, cevimeline or betahanechol (when pilocarpine proves ineffective); these measures moreover favor integrity of the oral mucosa (8,17).

5.Dysgeusia

According to some estimates, 50-75% of all cancer patients who receive chemotherapy, radiotherapy or both can experience alterations in taste perception (8).

- Etiopathogenesis

The main cause of dysgeusia in cancer patients is the action of chemotherapy and radiotherapy upon oral epithelial cell turnover, and the effects of such treatments upon nerves, taste buds and olfactory receptors (4,10). On the other hand, anticancer drugs can access the oral cavity through diffusion from plasma in the capillaries, producing an unpleasant taste (8,20). The mechanisms underlying dysgeusia also may be related to modifications in the concentrations of sodium, potassium and calcium in the taste bud cell receptors (20). Other causes are candidiasis, viral infections and gingivitis, among others.

- Clinical characteristics

The patients present distorted taste sensation, describing a metallic or very salty taste of food. These situations can adversely affect patient food intake and nutritional condition.

- Measurement of taste sensitivity

The evaluation of patients with taste alterations requires a good case history, together with specific questioning (8). We can also deposit solutions with the primary flavors on the back of the tongue, with the purpose of determining whether the patient is able to correctly identify the flavors. Another much less frequently used test is electric stimulation (galvanometry), delivering an electric current of several microamperes onto the back of the tongue, to assess patient capacity to identify the stimulus.

- Treatment

Although dysgeusia has multiple origins, there are simple forms of treatment, such as a reduction of the dose of certain chemotherapeutic drugs (e.g., histone deacetylase inhibitors), the treatment of oral infections, and dietetic counseling (8,20). In relation to this latter aspect, it is advisable to increase liquid intake with meals, and chew food slowly - thereby freeing more flavors and especially increasing saliva production. In addition, diversity during meals is advisable, in order to prevent taste bud adaptation to flavors. Other pharmacological strategies include zinc supplements and amifostine. However, the results obtained in different clinical trials have not been entirely satisfactory, and other treatment alternatives, such as vitamin D supplements, are therefore being investigated (8).

6.Infections

Cytostatic agents can affect the bone marrow, producing anemia, leukopenia and thrombopenia. As a result of their indirect toxicity mechanism, the oral cavity becomes more vulnerable to infections approximately one week following the administration of these drugs. Bone marrow function must be evaluated, since the reduction or absence of inflammatory phenomena causes the oral tissues to appear normal; infections therefore go unnoticed, and septicemia may result. It should be noted that apart from causing frequent infections, agranulocytosis also produces neutropenic ulcers, which are characterized by a central necrotic area, no perilesional erythematous halo, and irregular margins. These ulcerations are generally large and painful, and may be covered by a...
fibrin membrane. They appear in both keratinized and non-keratinized tissues, and are associated with granulocyte counts of under 800 cells/μl.

• Bacterial infections
During chemotherapy, saprophytic bacteria can become aggressive as a result of the decreased granulocyte presence and increased fragility of the oral mucosa. A number of bacteria, such as *Streptococcus viridans*, *Prevotella*, *Fusobacterium*, *Actinobacillus*, *Actinomyces* and *Actinomyces* are associated with infections of the oral cavity in patients receiving chemotherapy (8). Bacterial infections usually manifest locally in the gingival tissue, mucosa and teeth. Necrotizing gingivitis is the most frequent oral manifestation, accompanied in some cases by fever and adenopathies, particularly in patients with previous periodontal conditions. These infections are usually treated administering a combination of penicillins and metronidazole, with subsequent dental treatment (e.g., tartrectomy).

• Fungal infections
The majority of fungal infections of the oral cavity are produced by *Candida albicans* (4). The most prevalent forms of candidiasis are the pseudomembranous presentation, followed by erythematous candidiasis and angular cheilitis (4,8). Oral infection may give rise to sepsis and can prove fatal if not adequately diagnosed, especially when caused by non-*C. albicans* species such as *Candida tropicalis* (8). The diagnosis is based on the clinical appearance of the lesions, the ease with which the necrotic surface of the lesions can be removed by friction, and potassium hydroxide smear preparations, which reveal the presence of the fungus (5). Although prophylactic treatment with antifungal drugs has been questioned, good results have been obtained with such treatment in immune suppressed and/or neutropenic patients (8). In the review of 17 studies published by Lalla et al., the prophylactic administration of fluconazole during cancer therapy was seen to reduce the prevalence of clinically manifest fungal infections, including systemic infections, to 1.9% (8). Topical and systemic antifungal treatment is used for oral candidiasis, combining nystatin (100,000 IU/ml 3-4 times/day) and fluconazole (100 mg/day) or ketoconazole (200 mg/day). In the case of resistance to these drugs, use is made of itraconazole (200-400 mg/day) or amphotericin B, in patients with very extensive and severe infections (20 mg/day) (4,8).

• Viral infections
In most cases, viral infections produced by herpes simplex virus, varicella zoster virus and Epstein-Barr virus are the result of reactivation of a latent virus, while infections produced by cytomegalovirus can be due to reactivation of a latent virus or the action of a recently acquired virus (4,8).

* Infection produced by herpes simplex virus (HSV): The incidence of oral lesions produced by recurrent HSV in cancer patients with bone marrow suppression has decreased considerably following the introduction of prophylactic acyclovir (4,8). In patients without antiviral prophylaxis, the oral lesions generally manifest with chemotherapy or chemotherapy-radiotherapy during the most intense immune suppression period. The clinical picture tends to be atypical, with painful ulcerations as a first manifestation. These lesions are crater-shaped, well-defined with whitish margins, and are mainly located on the palate and gums (21). The ulcers tend to progress towards mucocutaneous lesions in a short period of time, and are slow in healing. The diagnosis is usually based on the clinical findings, though in some cases viral culture and isolation is recommended in order to confirm the diagnosis and avoid spreading of the lesions (21). Treatment consists of acyclovir via the oral (200-400 mg/3-5 times a day) or intravenous route (5 mg/kg in infusion during one hour every 8-12 hours), for as long as lesions remain (8,22). We can also use oral valacyclovir (500-100 mg twice a day), though the review published by Glenny et al. (22) did not find this form of therapy to be more effective than acyclovir. In the case of resistance to the drug, intravenous foscarnet or cidofovir is an alternative option.

* Infection produced by Epstein-Barr virus (EBV): There have been reports of hairy leukoplakia in patients subjected to chemotherapy due to acute myeloid leukemia, acute lymphocytic leukemia and multiple myeloma (8). The infection is clinically characterized by elongated and elevated white lesions located bilaterally at the lateral margins of the tongue. The lesions are not removed by rasping, and produce no symptoms. In general, no treatment is indicated, since the lesions improve as the host immune function recovers, and they do not undergo malignant transformation – though high-dose oral valacyclovir is a safe and effective management option (23). Topical treatments in the form of 25% podophyllin resin either alone or in combination with topical 5% acyclovir and gentian violet have also been found to be safe and effective (8).

* Infection produced by varicella-zoster virus (VZV): In contrast to HSV, the orofacial lesions produced by VZV generally manifest several weeks after the interruption of chemotherapy (4). The patients may experience a series of nonspecific prodromic symptoms (pain or dysesthesias), followed by a vesicular eruption along a dermatome innervated in the maxillofacial territory by a trigeminal nerve branch – though in some cases multiple dermatomes can be affected; the lesions may exhibit a more generalized distribution with more extensive skin necrosis; or alternatively there may be extensive hematoge-
nous spread towards mucocutaneous structures and also internal organs. The pain is described as constant and burning, and the vesicles (blisters) appear both on the skin and on the mucosal membranes, without extending beyond the midline. Depending on the immune depression of the patient, treatment consists of acyclovir (800 mg 5 times a day during 5-7 days via the oral route, or 5-10 mg/kg three times a day during 5 days via the intravenous route), oral famcyclovir or valacyclovir, or intravenous foscarnet (40 mg/kg three times a day) in the case of resistance to the aforementioned drugs. Amitriptyline (25-50 mg/day via oral) or anticonvulsivants (clonazepam, carbamazepine) can be used to treat the pain.

Infection produced by cytomegalovirus (CMV):
- The lesions produced by CMV consist of multiple nonspecific, pseudomembranous ulcerations covered by a fibrin exudate, with a granulomatous base and irregular margins. At present, gancyclovir is the treatment of choice in cases of acute CMV infection (4).

7. Bleeding tendency
- Etiopathogenesis
Bleeding tendency is secondary to bone marrow suppression caused by chemotherapy or the liver toxicity of certain cytostatic drugs, resulting in alteration of the synthesis of different coagulation factors. Bleeding tendency in the oral cavity usually appears after trauma during chewing in patients with pre-existing periodontal disease - especially patients with prior gingivitis and a platelet count of under 20,000 platelets/mm³.

- Clinical characteristics
Clinically, we can observe petechiae, ecchymosis, hematomas or diffuse bleeding in any location of the oral cavity.

- Treatment
Oral rinses with 0.12% chlorhexidine avoid overinfection and can help eliminate remaining blood, though caution is required not to disturb the blood clots, since this may lead to further bleeding (4). The treatment of choice in cases of bleeding consists of vasoconstrictors such as topical norepinephrine, mucoceradherent tissue protectors such as cyanoacrylate, and coagulation-favoring drugs such as topical thrombin or hemostatic collagen, which organize and stabilize the blood clots (4). In individuals subjected to chemotherapy who require invasive dental treatment, the hematological condition of the patient must be taken into account, with consultation of the supervising oncologist. In the presence of a platelet count of under 50,000 platelets/mm³, it is advisable to provide invasive dental treatment in the hospital setting, following transfusion assessment.

8. Osteonecrosis of the jaws due to bisphosphonates
- Terminology
Bisphosphonates (BPs) are potent inhibitors of osteoclastic bone reabsorption and have been used for decades for the treatment of osteoporosis, malignant hypercalcemia,
solid tumor bone metastases and myeloma (4,24,25). In the year 2003, Marx published a first series of 36 patients with osteonecrosis of the jaws (ONJ) induced by the BPs zoledronate and pamidronate (26). Posteriorly, Ruggiero et al. published a larger series of 63 patients (27). In Spain, Bagán et al., in the year 2005, published a series of 10 patients subjected to chemotherapy with BPs, and who developed osteonecrosis of the jaws (28). With the purpose of exploring the growing problem posed by this new disorder, the American Association of Oral and Maxillofacial Surgeons (AAOMS)(29) in 2007 defined the diagnostic criteria of osteonecrosis of the jaws induced by bisphosphonates. During that same year in Spain, a panel of experts in Oncology, Hematology, Urology, Stomatology / Odontology and Maxillofacial Surgery published a series of recommendations for patients treated with BPs (30).

- **Etiopathogenesis**

The etiology of ONJ remains unclear, and although the underlying mechanism of action has not been fully established, a series of factors are believed to be involved. In this context, it has been postulated that BPs produce osteoclast apoptosis, thereby inhibiting bone resorption and bone remodeling, and favoring the creation of areas of bone sequestration (4,24,25,30-33). On the other hand, it has been suggested that inhibition of this homeostatic cycle gives rise to the accumulation of non-vital osteocytes and microfractures in the old bone matrix, thereby facilitating the progression of ONJ (25). Some studies in turn relate ONJ to an increase in bacterial microfilm, favoring bacterial adherence to the surface of the tooth – particularly bacteria belonging to the genus *Actinomyces*. This could explain why such osteonecrosis only appears in the oral cavity (24,25). On the other hand, BPs may produce blood vessel obstruction within bone, and consequently necrosis of the osteocytes surrounding these vessels. By inhibiting angiogenesis, healing is delayed (25,31-33). In relation to this phenomenon, ONJ has also been observed in patients treated with bevacizumab (25). The inhibition of oral epithelial cell proliferation and migration produced by BPs may cause a delay in post-extraction socket healing. In turn, the accumulation of BPs produces alveolar bone sclerosis, complicating extraction and prolonging the healing time. Lastly, in patients of old age and/or subjected to treatment with chemotherapeutic drugs or corticosteroids, immune function may be altered, thereby increasing the susceptibility to infections (25,31) (Fig. 1).

- **Risk factors**

The development of ONJ has been associated to a number of general risk factors, such as the type of BP administered, the duration of treatment, the type of neoplasm, the existence of concomitant treatments (chemotherapy, head and neck radiotherapy, corticosteroids, thalidomide or bortezomib), and the presence of other disease conditions (anemia, diabetes, obesity, hypercalcemia and coagulation disorders)(25,32-36). Local risk factors in turn include dental/osteocclusive surgery, the mandibular location, bone protuberances (torus, mylohyoid crest) and concomitant oral disease (periodontal or dental infections) (4,25,34-36). Regarding hereditary factors, ONJ has been related to polymorphisms of cytochrome P450-2C19 [CYP2C8] and to the COLIA-1, RANK, MMP-2, OPG, OPN, FPPS and FCEV genes (25,33,35,37). Other contributing cofactors are alcohol, smoking, deficient oral hygiene, obesity and old age (25,33,32,36).

- **Incidence**

Osteonecrosis of the jaws produced by intravenous BPs is more frequent than ONJ due to oral BPs, with an incidence of 1-12% versus 0.01-0.04%, respectively (24,36,38). In the study published by Ruggiero et al. (34), based on case series, case-control series and cohort studies of patients treated with intravenous BPs up until the year 2006, the cumulative incidence varied between 0.8%-12%. In later studies such as that of Bagán et al. (2009), the suggested incidence was 1-3% (33). 5. **Clinical characteristics**

Clinically, the onset of ONJ can be nonspecific. The patient may describe discomfort around a tooth, a lack of healing after tooth extraction, or ulceration of the oral mucosa (4,31). As the lesions advance, the patient may develop pain, exposure of necrotic bone, fistulization, purulent secretion, alveolar nerve paresthesia, dental mobility, involvement of the maxillary sinus, and mandibular fracture (31,32,35). In 2006, Ruggiero et al. (39) proposed a staging system for ONJ based on the clinical characteristics of the lesion. In 2009, the AAOMS published a modification of the staging system developed by Ruggiero et al. (34), and posteriorly, in 2012, Bagán et al. (40) proposed a new classification of ONJ with the creation of two new subcategories in stage 2 (Table 3).

- **Complementary tests**

A routine panoramic X-ray study is indicated. Computed tomography or magnetic resonance imaging can be used to evaluate the magnitude and extent of necrotic bone, though the latter technique is less specific (30,33). Other complementary tests include culture and an antibiogram of the exposed zone. A biopsy is advised in cases of doubt in differentiating between ONJ and bone metastasis (4,30). The evaluation of serum C-terminal telopeptide (CTX) is subject to controversy; some studies have found no statistically significant relationship between the CTX levels and the size or number of exposed necrotic bone areas in ONJ (33,35).

- **Prevention**

Since the treatment of ONJ is usually unsatisfactory and the condition proves difficult to control, management should focus on the prevention of high risk situations, checking the oral cavity with the purpose of carrying out treatment – especially when of a surgical nature.
Table 3. Clinical classification of ONJ developed by Ruggiero (2006), posteriorly modified by the American Association of Oral and Maxillofacial Surgeons (AAOMS, 2009) and the classification of Bagán et al. (2012) (39,34,40). BRONJ: bisphosphonate-related osteonecrosis of the jaw.

| BRONJ STAGE | DESCRIPTION | BRONJ STAGE | DESCRIPTION | TREATMENT |
|-------------|-------------|-------------|-------------|-----------|
| STAGE 0     | No clinical evidence of necrotic bone. Nonspecific clinical findings and symptoms. | STAGE 0     | No clinical evidence of necrotic bone. Nonspecific clinical findings and symptoms. | Symptomatic treatment, including analgesics and antibiotics. |
| STAGE 1     | Bone exposure. Necrotic bone. Asymptomatic. No clinical evidence of infection. | STAGE 1     | Bone exposure with necrotic bone or a small ulceration of the oral mucosa without necrotic bone exposure. Both forms would be asymptomatic. | Daily rinse with 0.12% chlorhexidine + follow-up. |
| STAGE 2     | Bone exposure. Necrotic bone. Pain and infection of the soft tissues/bone. | STAGE 2A    | Bone exposure with necrotic bone or a small ulceration of the oral mucosa without necrotic bone exposure, but with symptoms: pain and infection of the soft tissues/bone. Can be controlled by conservative measures and does not progress. | Daily rinse with 0.12% chlorhexidine + antibiotics + analgesics + follow-up. |
| STAGE 2B    | Bone exposure with necrotic bone or a small ulceration of the oral mucosa without necrotic bone exposure, but with symptoms: pain and infection of the soft tissues/bone. Not controlled by conservative treatment, and necrosis or the derived infectious signs are seen to progress. | | | Daily rinse with 0.12% chlorhexidine + antibiotics + analgesics + surgery with elimination of the bone necrosis. |
| STAGE 3     | Bone exposure. Necrotic bone. Pain, infection and one or more of the following: pathological fracture, extraoral fistula or osteolysis extending to the lower mandibular margin or floor of the maxillary sinus. | STAGE 3     | Bone exposure. Necrotic bone. Pain, infection and one or more of the following: pathological fracture, extraoral fistula or osteolysis extending to the lower mandibular margin or floor of the maxillary sinus. | Daily rinse with 0.12% chlorhexidine + antibiotics + analgesics + extensive surgery with bone resection. |

- between 4-6 weeks before the first infusion of BPs (4,25,30,35). If the patient is receiving treatment with BPs, it is advisable to evaluate the oral cavity every 6-12 months (4,30,35), and any required dental treatment should follow a series of measures designed to lessen the risk of ONJ, since some therapies are considered acceptable while others are contraindicated (4,32,34,35).

**Treatment**

The treatment of ONJ is controversial, and no effective or fully consensus-based guidelines have been established, though a number of management strategies have been used, such as the interruption of BPs, surgical treatment, the use of hyperbaric oxygen, and the application of ozone, laser surgery, or low-intensity laser therapy (25,30-32,34,35,38). Research is still being conducted on the efficacy of the treatment of ONJ with pentoxyphylline, α-tocopherol or teriparatide (38). Most authors agree that conservative management of ONJ is the best approach (4,28,35), since mucosal healing can be achieved in at least 23-53% of all patients by adopting less aggressive treatments (33).

**References**

1. Ruiz-Esquide G, Nervi B, Vargas A, Maíz A. Treatment and prevention of cancer treatment related oral mucositis. Rev Med Chil. 2011;139:373-81.
2. Watters AL, Epstein JB, Agulnik M. Oral complications of targeted cancer therapies: a narrative literature review. Oral Oncol. 2011;47:441-8.
3. López-Galindo MP, Bagán JV, Jiménez-Soriano Y, Alpiste F, Camps C. Clinical evaluation of dental and periodontal status in a group of oncological patients before chemotherapy. Med Oral Patol Oral Cir Bucal. 2006;11:E17-21.
4. Chaveli López B, Gavaldá Esteve C, Sarrión Pérez MG. Dental treatment considerations in the chemotherapy patient. J Clin Exp Dent. 2011;3:e31-42.
5. Caribe-Gomes F, Chimeno-Küstner E, López-López J, Finestres-Zubeldia F, Guix-Melcior B. Dental management of the complications of radio and chemotherapy in oral cancer. Med Oral. 2003;83:178-87.
6. López-Castaño F, Oñate-Sánchez RE, Roldán-Chicanó R, Cabrero-Merino MC. Measurement of secondary mucositis to oncohematologic treatment by means of different scale. Review. Med Oral Patol Oral Cir Bucal. 2005;10:412-21.
7. Chan CW, Chang AM, Molassiotis A, Lee IY, Lee GC. Oral complications in Chinese cancer patients undergoing chemotherapy. Support Care Cancer. 2003;1:48-55.
8. Mosel DD, Bauer RL, Lynch DP, Hwang ST. Oral complications in the treatment of cancer patients. Oral Dis. 2011;17:550-9.
9. Keefe DM, Schubert MM, Elting LS, Sonis ST, Epstein JB, Raber-Durlacher JE, et al. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer. 2007;109:820-31.
10. Epstein JB, Tsang AH, Warkentin D, Ship JA. The role of salivary function in modulating chemotherapy-induced oropharyngeal mucositis: a review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002;94:39-44.

11. Giles FJ, Miller CB, Hurd DD, Wingard JR, Fleming TR, Sonis ST, et al. A phase III, randomized, double-blind, placebo-controlled, multinational trial of iseganan for the prevention of oral mucositis in patients receiving stomatotoxic chemotherapy (PROMPT-CT trial). Leuk Lymphoma. 2003;44:1165-72.

12. Worthington HV, Clarkson JE, Eden OB. Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst Rev. 2007;4:CD000978.

13. Schmidt E, Thommissen NH, Rudat A, Bieker R, Schliemann C, Mesters RM, et al. Use of palifermin for the prevention of high-dose methotretate-induced oral mucositis. Ann Oncol. 2008;19:1644-9.

14. Peterson DE, Jones JB, Petit RG 2nd. Randomized, placebo-controlled trial of Safforis for prevention and treatment of oral mucositis in breast cancer patients receiving anthracycline-based chemotherapy. Cancer. 2007;109:322-31.

15. Innocenti M, Moscattelli G, Lopez S. Efficacy of gelclair in reducing pain in palliative care patients with oral lesions: preliminary findings from an open pilot study. J Pain Symptom Manage. 2002;24:456-7.

16. Chen YK, Hou HA, Chow JM, Chen YC, Hsueh PR, Tien HF. The impact of oral herpes simplex virus infection and candidiasis on chemotherapy-induced oral mucositis among patients with hematological malignancies. Eur J Clin Microbiol Infect Dis. 2011;30:753-9.

17. Avşar A, Ellı M, Darka O, Pınarlı G. Long-term effects of chemotherapy on caries formation, dental development, and salivary factors in childhood cancer survivors. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;104:781-9.

18. Oğuz A, Cetiner S, Karadeniz C, Alpaslan G, Alpaslan C, Pınarlı G. Long-term effects of chemotherapy on odontal structures in children with non-Hodgkin’s lymphoma. Eur J Oral Sci. 2004;112:8-11.

19. Rojas-Morales T, Lugo Z, Santana Y, Navas R, Zambrano O, Viera N, et al. Capacity buffer of the saliva in children and adolescents with cancer: Variations induced by the administration of Metotrexate or Cyclophosphamide. Med Oral Patol Oral Cir Bucal. 2005;10:E103-8.

20. Cowart BJ. Taste dysfunction: a practical guide for oral medicine. Oral Dis. 2011;17:2-6.

21. Sepúlveda E, Brethauer U, Rojas J, Fernández E, Le Fort P. Oral ulcers in children under chemotherapy: clinical characteristics and their relation with Herpes Simplex Virus type 1 and Candida albicans. Med Oral Patol Oral Cir Bucal. 2005;10:E103-8.

22. Gleneny AM, Fernandez Mauleffinch LM, Pavitt S, Walsh T. Interventions for the prevention and treatment of herpes simplex virus in patients being treated for cancer. Cochrane Database Syst Rev. 2009;1:CD006706.

23. Walling DM, Flaitz CM, Nichols CM. Epstein-Barr virus replication in oral hairy leukoplakia: response, persistence, and resistance to treatment with valacyclovir. J Infect Dis. 2003;188:883-90.

24. Filleule O, Crompt O, Saussez S. Bisphosphonate-induced osteonecrosis of the jaw: a review of 2,400 patient cases. J Cancer Res Clin Oncol. 2010;136:1117-24.

25. Yoneda T, Hagino H, Sugimoto T, Ohta H, Takahashi S, Soen S, et al. Bisphosphonate-related osteonecrosis of the jaw: position paper from the Allied Task Force Committee of Japanese Society for Bone and Mineral Research, Japan Osteoporosis Society, Japanese Society of Periodontology, Japanese Society for Oral and Maxillofacial Radiology, and Japanese Society of Oral and Maxillofacial Surgeons. J Bone Miner Metab. 2010;28:365-83.

26. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61:1115-7.

27. Ruggiero SL, Mehrtra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004;62:527-34.

28. Bagan JV, Murillo J, Jimenez Y, Poveda R, Militan MA, Sanchis JM, et al. Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases. J Oral Pathol Med. 2005;34:120-3.

29. Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2007;65:369-76.

30. Bagan J, Blade J, Cozar JM, Constela M, Garcia Sanz R, Gomez Veiga F, et al. Recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw (ONJ) in cancer patients treated with bisphosphonates. Med Oral Patol Oral Cir Bucal. 2007;12:E336-40.

31. Gómez Font R, Martínez García ML, Olmos Martínez JM. Osteonecrosis of the jaws due to bisphosphonate treatments. Med Oral Patol Oral Cir Bucal. 2008;13:E318-24.

32. Vescovi P, Merigo E, Meleti M, Manfredi M, Guidotti R, Nammour S. Bisphosphonates-related osteonecrosis of the jaws: a concise review of the literature and a report of a single-centre experience with 151 patients. J Oral Pathol Med. 2012;41:214-21.

33. Bagan J, Scully C, Sabater V, Jimenez Y. Osteonecrosis of the jaws in patients treated with intravenous bisphosphonates (BRONJ): A concise update. Oral Oncol. 2009;45:551-4.

34. Ruggiero SL, Dodson TB, Assael LA, Landsberg R, Marx RE, Mehrtra B, et al. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw - 2009 update. Aust Endod J. 2009;35:119-30.

35. Fedele S, Kumar N, Davies R, Fiske J, Greening S, Porter S. Dental management of patients at risk of osteonecrosis of the jaws: a critical review. Oral Dis. 2009;15:527-37.

36. Chaveli López B, Sarrión Pérez MG, Jiménez Soriano Y. Dental considerations in pregnancy and menopause. J Clin Exp Dent. 2011;3:e135-44.

37. Arduino PG, Menegatti E, Scoletta M, Battaglio C, Mozzati M, Chiecchio A, et al. Vascular endothelial growth factor genetic polymorphisms and haplotypes in female patients with bisphosphonate-related osteonecrosis of the jaws. J Oral Pathol Med. 2011;40:510-5.

38. Vescovi P. Bisphosphonates and osteonecrosis: an open matter. Clin Cases Miner Bone Metab. 2012;9:142-4.

39. Ruggiero S, Gralow J, Marx RE, Hoff AO, Schubert MM, Huryn JM, et al. Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. J Oncol Pract. 2006;2:7-14.

40. Bagan JV, Hens-Aumente E, Leopoldo-Rodado M, Poveda-Roda R, Bagan L. Bisphosphonate-related osteonecrosis of the jaws: study of the staging system in a series of clinical cases. Oral Oncol. 2012;48:753-7.

Conflict of interest

The authors declare that they have no conflict of interest.